Navigation Links
Precision Optics Corporation, Inc. Announces Operating Results for the First Quarter Ended September 30, 2012
Date:11/15/2012

GARDNER, Mass., Nov. 15, 2012 /PRNewswire/ -- Precision Optics Corporation, Inc. (OTCQB: PEYE) (the "Company") announces operating results for the first quarter of fiscal year 2013 ended September 30, 2012.

Revenues for the quarter ended September 30, 2012, were $563,398 compared to $504,749 for the same period last year, representing an increase of 11.6%.

Net loss for the quarter ended September 30, 2012, was $358,094, or $.27 per fully-diluted share, compared to net income of $1,998,441, or $1.15 per fully-diluted share, for the quarter ended September 30, 2011.  Net income in the quarter ended September 30, 2011 includes a non-recurring gain on the sale of patents of $2,276,286, which when removed, leaves a pro forma net loss in the quarter ended September 30, 2011 of $277,845.  The increase in the net loss in the quarter ended September 30, 2012 over the pro forma net loss in the quarter ended September 30, 2011, as adjusted for the removal of the non-recurring gain, is primarily attributable to lower gross margins as a result of new product start-up manufacturing costs and higher research and development expenses.

Cash and cash equivalents were $2,337,694 at September 30, 2012.  As previously announced, in September 2012 the Company completed a private offering to accredited investors of units of common stock and common stock purchase warrants generating gross proceeds of approximately $2.5 million, with net proceeds of approximately $2.2 million available immediately for the Company's general working capital needs.

The year-over-year increase in quarterly revenues resulted from increases in the Company's ongoing sales of previously developed products, as well as a newly designed addition to the Company's line of advanced surgical visualization products for use in spinal surgery.  The Company is currently completing pre-production activities to enable shipments against previously announced orders for products incorporating Microprecision™ technology for very small endoscopes and micro medical cameras with diameters on the order of 1 millimeter and smaller.  Operational efforts are also focused on sales and marketing strategies intended to broaden awareness of the benefits of the Company's new technology platform, which the Company believes is ready for general application to medical device projects requiring surgery-grade visualization from sub-millimeter sized devices.

About Precision Optics Corporation 

Precision Optics Corporation has been a leading developer and manufacturer of advanced optical instruments since 1982.  The Company designs and produces next generation medical instruments, Microprecision™ micro-optics with characteristic dimensions less than 1 millimeter, and other advanced optical systems based on the Company's proprietary optical technologies. The Company's innovative medical instrumentation line includes state-of-the-art endoscopes and endocouplers as well as custom illumination and imaging products for use in minimally invasive surgical procedures. The Company's website is www.poci.com. Investors can find Real-Time quotes and market information for the Company on www.otcmarkets.com/stock/PEYE/quote.

About Forward-Looking Statements 

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements related to our future activities or future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by our management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in our annual report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.


'/>"/>
SOURCE Precision Optics Corporation, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. TechPrecision Receives Additional Medical Purchase Orders Exceeding $1.5 Million
2. Precision Automation Expert DWFritz Automation Announces Website Launch www.DWFritz.com
3. Plainfield Precision Achieves ISO 13485:2003 Quality Management Certification for Medical Device Manufacturing
4. Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 2012
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Global Medical Fiber Optics Industry
7. Denton Vacuum Ships Breakthrough Wafer-level Optics Development System to Leading German R&D Organization
8. Inrad Optics, Inc. Announces Financial Results For First Quarter 2012
9. Statement from Mary Vogt, President of Home Access Health Corporation, manufacturer of the Home Access HIV-1 test system, the only over-the-counter HIV test previously approved by the FDA for at-home use.
10. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
11. AspenBio Pharma Announces Pricing of Public Offering of 1,476,000 Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that its ... Inc., has recently opened a New York City Office in ... of its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. ... Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS accreditation ... ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... Mich. , Aug. 7, 2017 Diplomat Pharmacy, ... of Joel Saban as president, effective Aug. 7, ... Urick has decided to pursue other interests and will ... "During his tenure, Paul has served us in multiple leadership ... Specialty Pharmacy in Jun. 2015 and has provided decisive, strategic ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... ... Maury Regional Health has announced a large-scale adoption of AccuVein vein visualization ... Regional Medical Center is making vein visualization part of their standard of care. , ... importantly, helps our staff members locate a vein that will provide good access to ...
(Date:8/16/2017)... ... August 16, 2017 , ... A global leader in the treatment ... clinics in all 29 Indian states—bringing the country one step closer to eliminating clubfoot ... the nonprofit organization is on track to enroll 10,000 children in the clubfoot treatment ...
(Date:8/16/2017)... ... , ... Fusion Flix Inc., a Telly Award Winning, Non Profit Corporation has ... viewers in a partnership with the Amazon Video Direct Streaming Distribution Platform. , Their ... Ray disc in 2018. Proceeds will be going to further health research. , ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... TopConsumerReviews.com recently ... Lab Testing . , The healthcare industry in the United States has undergone ... are the days of needing to have a doctor’s order to get a blood ...
(Date:8/16/2017)... , ... August 16, 2017 , ... First Choice ... States, named Dr. Douglas J. Harrison, as the new Medical Director of its Sienna ... new facility Medical Director of our Sienna Plantation location,” said Dr. Michael (Derek) Caraway, ...
Breaking Medicine News(10 mins):